Salarius Posts Q2 Net Loss of $5.5M, Continues Equity Funding

Ticker: DCOY · Form: 10-Q · Filed: Aug 12, 2025 · CIK: 1615219

Sentiment: bearish

Topics: Biotechnology, Pre-revenue, Net Loss, Equity Financing, Dilution Risk, R&D Expenses, SEC Filing

Related Tickers: DCOY

TL;DR

**DCOY is burning cash with no revenue, relying on dilutive equity raises to stay afloat – avoid unless you love high-risk biotech bets.**

AI Summary

Salarius Pharmaceuticals, Inc. (DCOY) reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, indicating its pre-commercial stage. The company's net loss for the three months ended June 30, 2025, was $5.5 million, a slight increase from the $5.4 million net loss in the same period of 2024. For the six months ended June 30, 2025, the net loss was $11.0 million, up from $10.8 million in the first half of 2024. Research and development expenses decreased to $3.5 million for the three months ended June 30, 2025, from $3.7 million in the prior year, and to $7.0 million for the six months ended June 30, 2025, from $7.4 million in 2024. General and administrative expenses increased to $2.0 million for the three months ended June 30, 2025, from $1.7 million in 2024, and to $4.0 million for the six months ended June 30, 2025, from $3.4 million in 2024. The company continues to fund operations through equity offerings, having sold 5.5 million shares of common stock for net proceeds of $0.125 million through an At-The-Market offering during the six months ended June 30, 2025. Salarius also entered into a Purchase Agreement on December 12, 2024, with an institutional investor for up to $20.0 million in common stock, with $0.125 million already drawn in Q2 2025.

Why It Matters

For investors, Salarius's continued lack of revenue and reliance on equity financing, including the recent At-The-Market offering and Purchase Agreement, signals high risk and dilution potential. Employees face uncertainty given the company's pre-revenue status and ongoing need for capital to fund drug development. Customers, specifically future patients, are impacted by the progress (or lack thereof) in clinical trials for Salarius's drug candidates, which are crucial for its long-term viability. In the competitive biotech landscape, Salarius's ability to secure funding and advance its pipeline against larger, more established pharmaceutical companies is paramount for its survival and market relevance.

Risk Assessment

Risk Level: high — Salarius Pharmaceuticals is a high-risk investment due to its pre-revenue status, reporting $0 revenue for both the three and six months ended June 30, 2025. The company incurred net losses of $5.5 million and $11.0 million for these respective periods, indicating significant cash burn without a commercial product. Its reliance on dilutive equity financing, such as the $0.125 million raised through an At-The-Market offering and the $20.0 million Purchase Agreement, further highlights its precarious financial position.

Analyst Insight

Investors should exercise extreme caution and consider avoiding Salarius Pharmaceuticals (DCOY) given its pre-revenue stage, consistent net losses, and heavy reliance on dilutive equity financing. Only investors with a high-risk tolerance and a deep understanding of early-stage biotech development should consider a speculative position, acknowledging the significant risk of further dilution and potential for capital loss.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$11.0M
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
0.0%

Revenue Breakdown

SegmentRevenueGrowth
Pharmaceuticals$00.0%

Key Numbers

Key Players & Entities

FAQ

What were Salarius Pharmaceuticals' revenues for Q2 2025?

Salarius Pharmaceuticals, Inc. reported no revenue for the three months ended June 30, 2025, consistent with the $0 revenue reported for the same period in 2024.

How much was Salarius Pharmaceuticals' net loss in Q2 2025?

Salarius Pharmaceuticals, Inc. recorded a net loss of $5.5 million for the three months ended June 30, 2025, which is a slight increase from the $5.4 million net loss in Q2 2024.

What were Salarius Pharmaceuticals' R&D expenses for the first half of 2025?

For the six months ended June 30, 2025, Salarius Pharmaceuticals' research and development expenses were $7.0 million, a decrease from $7.4 million in the first half of 2024.

How is Salarius Pharmaceuticals funding its operations?

Salarius Pharmaceuticals is funding its operations primarily through equity offerings, including an At-The-Market offering that generated $0.125 million in net proceeds from selling 5.5 million shares in the first half of 2025, and a Purchase Agreement for up to $20.0 million with an institutional investor.

What is the significance of the Purchase Agreement for Salarius Pharmaceuticals?

The Purchase Agreement, entered into on December 12, 2024, allows Salarius Pharmaceuticals to sell up to $20.0 million of common stock to an institutional investor, providing a crucial source of capital for its ongoing operations and drug development, with $0.125 million already drawn in Q2 2025.

Did Salarius Pharmaceuticals experience an increase or decrease in general and administrative expenses?

Salarius Pharmaceuticals experienced an increase in general and administrative expenses, rising to $2.0 million for the three months ended June 30, 2025, from $1.7 million in the prior year period.

What are the primary risks for investors in Salarius Pharmaceuticals?

Primary risks for investors in Salarius Pharmaceuticals include its pre-revenue status, consistent net losses of $5.5 million in Q2 2025, and heavy reliance on dilutive equity financing, which can reduce the value of existing shares.

When was the latest 10-Q filed by Salarius Pharmaceuticals?

Salarius Pharmaceuticals, Inc. filed its latest 10-Q on August 12, 2025, for the period ended June 30, 2025.

What is Salarius Pharmaceuticals' business classification?

Salarius Pharmaceuticals, Inc. is classified under Pharmaceutical Preparations (SIC 2834), indicating its focus on drug development.

How many shares did Salarius Pharmaceuticals sell through its At-The-Market offering in the first half of 2025?

Salarius Pharmaceuticals sold 5.5 million shares of common stock through its At-The-Market offering during the six months ended June 30, 2025, generating net proceeds of $0.125 million.

Risk Factors

Industry Context

The pharmaceutical industry is characterized by high R&D costs, long development cycles, and stringent regulatory hurdles. Companies like Salarius operate in a competitive landscape where innovation is key, but success is contingent on navigating clinical trials and gaining market approval. The sector is also subject to significant investor scrutiny regarding pipeline progress and financial sustainability.

Regulatory Implications

Salarius, as a pharmaceutical developer, is subject to rigorous oversight by regulatory bodies like the FDA. The success of its drug candidates hinges on meeting strict efficacy and safety standards. Any delays or failures in clinical trials or the approval process pose significant regulatory and financial risks.

What Investors Should Do

  1. Monitor R&D Pipeline Progress
  2. Assess Future Funding Needs and Dilution
  3. Analyze Expense Management
  4. Evaluate Cash Burn Rate

Key Dates

Glossary

At-The-Market (ATM) Offering
A type of public offering where a company sells its shares directly into the open market over a period of time, typically through an intermediary like an investment bank. (Salarius used this to raise $0.125 million in H1 2025, highlighting its reliance on equity financing.)
Pre-commercial Stage
A phase in a company's lifecycle, particularly in the pharmaceutical or biotech industry, where it has not yet generated revenue from product sales, often focusing on research and development. (Salarius is in this stage, as indicated by zero revenue in the reported periods.)
Net Loss
The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (Salarius reported net losses of $5.5 million (Q2 2025) and $11.0 million (H1 2025), indicating ongoing operational costs without revenue.)
Research and Development (R&D) Expenses
Costs incurred by a company in the process of developing new products or services, or improving existing ones. (These expenses decreased slightly to $3.5 million (Q2 2025) and $7.0 million (H1 2025), suggesting a potential shift or efficiency in development efforts.)
General and Administrative (G&A) Expenses
Costs associated with the overall management and operation of a business, not directly tied to a specific product or service. (These expenses increased to $2.0 million (Q2 2025) and $4.0 million (H1 2025), which is a point of concern given the lack of revenue.)

Year-Over-Year Comparison

Compared to the prior year's periods, Salarius Pharmaceuticals reported no revenue for both Q2 and H1 2025, consistent with its pre-commercial stage. Net losses have slightly increased, with Q2 2025 at $5.5 million versus $5.4 million in Q2 2024, and H1 2025 at $11.0 million versus $10.8 million in H1 2024. Research and development expenses decreased year-over-year, while general and administrative expenses saw an increase, suggesting a shift in operational focus or cost structure.

Filing Stats: 4,473 words · 18 min read · ~15 pages · Grade level 17.9 · Accepted 2025-08-12 17:27:44

Key Financial Figures

Filing Documents

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Cash Flows 7 Condensed Consolidated Statement s of Stockholders' Equity ( D eficit) 8 Notes to Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 25 Item 4.

Controls and Procedures

Controls and Procedures 25 PART II. Other Information Item 1.

Legal Proceedings

Legal Proceedings 26 Item 1A.

Unregistered Sales of Equity Securities and Use of Proceeds 26

Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 26

Defaults Upon Senior Securities

Item 3 Defaults Upon Senior Securities 26

Mine Safety Disclosures 26

Item 4 Mine Safety Disclosures 26

Other Information 26

Item 5 Other Information 26 Item 6. Exhibits 31

SIGNATURES

SIGNATURES 34 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Various statements made in this Quarterly Report on Form 10-Q are forward-looking and involve risks and uncertainties. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements give our current expectations or forecasts of future events and are not statements of historical or current facts. These statements include, among others, statements about: our ability to continue as a going concern and support our operations beyond the second quarter of 2026; our expectations regarding the timing, likelihood, expected benefits of, and potential value created by, the proposed merger (the "Merger") between us and Decoy Therapeutics Inc. ("Decoy"); our expectations regarding the satisfaction of certain conditions to the completion of the Merger, including the conditions related to consummation of financing transactions with aggregate minimum proceeds of at least $6.0 million (the "Qualified Financing"), whether and when the Merger will be consummated and that our common stock remains listed on Nasdaq; the potential effects of the Merger on the ownership percentages of Decoy's stockholders and Salarius' stockholders in the combined company; our expectations regarding our clinical trials and any investigator-initiated clinical trials; our expectations as to revenue, cash flow, and expenses; our liquidity position, the expected sufficiency of such position for anticipated operating and capital requirements; and our expectations regarding our ability to regain compliance and remain listed on Nasdaq. Forward-looking statements also include statements other than statements of current or historical fact, including, without limitation, all

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements SALARIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2025 December 31, 2024 (Unaudited) (Audited) Assets Current assets: Cash and cash equivalents $ 794,886 $ 2,434,528 Prepaid expenses and other current assets 564,692 553,034 Total current assets 1,359,578 2,987,562 Other assets 33,200 35,412 Total assets $ 1,392,778 $ 3,022,974 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,481,949 $ 936,994 Accrued expenses and other current liabilities 740,553 352,419 Notes payable — 221,866 Total liabilities 2,222,502 1,511,279 Commitments and contingencies (Note 4) Stockholders' equity: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized; 0 issued and outstanding — — Common stock, $ 0.0001 par value; 100,000,000 shares authorized; 2,127,286 and 1,441,157 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 213 144 Additional paid-in capital 83,761,039 83,435,169 Accumulated deficit ( 84,590,976 ) ( 81,923,618 ) Total stockholders' equity (deficit) ( 829,724 ) 1,511,695 Total liabilities and stock holders'equity (deficit) $ 1,392,778 $ 3,022,974 See accompanying notes to condensed consolidated financial statements. 5 Table of Contents SALARIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 116,383 $ 214,447 $ 191,915 $ 457,449 General and administrative 849,182 1,253,070 2,492,345 2,781,683 Total operating expenses 965,565 1,467,517 2,684,260 3,239,132 Loss before other income (expense) ( 965,565 ) ( 1,467,517 ) ( 2,684,260 ) ( 3,239,132 ) Interest income, net 7,740 43,084 16,902 99,409 Loss from continuing operations ( 957,825 ) ( 1,424,433 ) ( 2,667,358 ) ( 3,139,723 ) Net loss $ ( 957,825 ) $ ( 1,424,433 ) $ ( 2,667,358 ) $ ( 3,139,723 )

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing